CIRCULATING TUMOR CELL DIAGNOSTICS FOR PROSTATE CANCER BIOMARKERSThe present invention describes a method for detecting castration-resistant prostate cancer (CRPC) in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological ...
Since there are no effective therapeutic options for advanced prostate cancer, early detection of this tumour is pivotal and can increase the curative success rate. Although the routine use of serum PSA testing has undoubtedly increased prostate cancer detection, one of its main drawbacks has been ...
Let us be your source to screen patients for the most commonly detected cancer in men in the US. We offer testing that can assist with screening, diagnosis, and management of prostate cancer. Hereditary Risk Assessment Our Guideline-Based Hereditary Cancer Panel helps evaluate potential risk for...
Artificial neural networks (ANNs) have only recently been applied to solve problems in the diagnosis, staging, and prediction of treatment outcome in prostate cancer. A literature search provided information on 10 published journal articles that were selected for review and analysis. In all but one...
The present invention describes a method for detecting NEPC in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating ...
Deep Bio, a local diagnostic company, said its prostate cancer analysis algorithm, DeepDx Prostate, will be integrated into Roche Diagnostics' Navify Digital Pathology platform.Through this collaboration, Deep Bio aims to enhance its digital pathology ca
“I was the primary investigator in a study that validated the performance of Ibex’s Prostate solution. At the end of the study, the team was most impressed with how well the algorithm preformed, with an area under the curve close to near perfect, not only for the diagnosis cancer but ...
Given that men over 60 are relatively more likely to develop prostate cancer than women, the growing elderly population worldwide is predicted to drive demand for prostate cancer diagnostics. A paper released in May 2023 by the American Society of Clinical Oncology states that older men are primar...
Prostate Cancer Nuclear Medicine Diagnostics MarketProstate cancer is cancer affecting the prostate glands in men. Prostate cancer is the second most common cancer after skin cancer in men. Several common factors accountable for the onset of prostate cancer are old age, family history, and race. Nu...
Your go-to source for the latest in diagnostics is here. Diagnostics World covers circulating tumor cells, liquid biopsy, point-of-care diagnostics, and more. Discover more today!